Fresenius Medical Care Selected To Provide Dialysis Care to More than 400 Patients...

Fri Jan 11, 2008 10:16am EST

* Reuters is not responsible for the content in this press release.

Fresenius Medical Care Selected To Provide Dialysis Care to More than 400 Patients in the U.K.

BAD HOMBURG, Germany--(Business Wire)--Fresenius Medical Care AG & Co. KGaA ("the Company") today
announced that it has been selected by the National Health System
(NHS) in the United Kingdom to manage dialysis care for 12 renal units
across the North of England.

   These clinics will provide dialysis treatments for more than 400
patients for approximately 7 years in North East and South Yorkshire
and Lincolnshire. Patients will remain under the care of their NHS
physicians, while benefiting from Fresenius Medical Care's dedication,
proven experience and expertise in hemodialysis.

   This pioneering program - part of the British Government's
involvement in independent sector partnerships to deliver more choice
and faster treatment to NHS patients - will see new renal dialysis
units developed and existing hospital facilities extended.

   While new satellite centers will open the door to more patients
and increase capacity, investment will also result in the installation
of state-of-the art equipment and the latest technology, as well as
the staff training and education.

   Dr. Emanuele Gatti, Chief Executive Officer for the regions
Europe, Middle East and Africa, commented: "We are very honored that
Fresenius Medical Care has been chosen to work in partnership with the
NHS to manage this innovative renal services program in the United
Kingdom. We now have an outstanding opportunity to improve capacity
for hemodialysis patients in the UK and provide easier access to
services. Patients and the healthcare system at large can clearly
benefit from our global expertise in renal care and our fully
vertically integrated business model."

   According to Kidney Research UK, a charity funding research that
focuses on kidney disease, between 600 to 800 patients per one million
population need renal replacement therapy in form of dialysis or
transplant for survival. Kidney Research expects the number of
end-stage renal disease (ESRD) patients to increase by about 5%
annually.

   The Company's subsidiary Fresenius Medical Care Renal Services UK
is the leading provider of dialysis services to the NHS in the UK,
operating 41 partnership dialysis units that provide chronic dialysis
treatment for about 2,800 NHS patients.

   Fresenius Medical Care is the world's largest integrated provider
of products and services for individuals undergoing dialysis because
of chronic kidney failure, a condition that affects more than
1,500,000 individuals worldwide. Through its network of 2,221 dialysis
clinics in North America, Europe, Latin America, Asia-Pacific and
Africa, Fresenius Medical Care provides dialysis treatment to 172,227
patients around the globe. Fresenius Medical Care is also the world's
leading provider of dialysis products such as hemodialysis machines,
dialyzers and related disposable products. Fresenius Medical Care is
listed on the Frankfurt Stock Exchange (FME, FME3) and the New York
Stock Exchange (FMS, FMS/P).

   For more information about Fresenius Medical Care visit the
Company's website at www.fmc-ag.com.

   This release contains forward-looking statements that are subject
to various risks and uncertainties. Actual results could differ
materially from those described in these forward-looking statements
due to certain factors, including uncertainties in the development of
the home dialysis market, the ability to develop and commercialize
technological innovations, changes in business, economic and
competitive conditions, regulatory reforms, foreign exchange rate
fluctuations, uncertainties in litigation or investigative
proceedings, and the availability of financing. These and other risks
and uncertainties are detailed in Fresenius Medical Care AG & Co.
KGaA's reports filed with the U.S. Securities and Exchange Commission.
Fresenius Medical Care AG & Co. KGaA does not undertake any
responsibility to update the forward-looking statements in this
release.

Fresenius Medical Care AG & Co. KGaA
Investor Relations
Oliver Maier, + 49 6172 609 2601
Fax: + 49 6172 609 2301
ir@fmc-ag.com
or
North America:
Terry L. Morris, + 1 800 948 2538
Fax: + 1 615 345 5605
ir@fmc-ag.com
www.fmc-ag.com

Copyright Business Wire 2008